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Abstract. Membrane-active antimicrobial peptides, such as polymyxin 
B (PxB), are currently in the spotlight as potential candidates to 
overcome bacterial resistance. We have designed synthetic analogs of 
PxB in order to determine the structural requirements for membrane 
action. Since the mechanism of action of PxB involves interaction with 
both the outer membrane and the cytoplasmic membrane of Gram 
negative bacteria, we have used an approach based on mimicking the 
outer layers of these membranes using monolayers, Langmuir-Blodgett 
films and unilamelar vesicles, and applying a battery of biophysical 
methods in order to dissect the different events of membrane 
interaction. Collectively, results indicate that the PxB analogues act in 
the bacterial membrane by the same mechanism than PxB, and that 
cationic amphipathicity determines peptide activity.   
  
Introduction 
 
 The global emergence and spread of multidrug-resistant bacteria (defined 
as resistant to three or more antibacterial drug classes) is an important clinical  
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problem. Some factors that have contributed to the development of bacterial 
resistance include inappropriate use of antibiotics, such as the overuse of 
powerful, broad-spectrum antibiotics, the presence of antibiotics in the 
food/livestock industry and the inclusion of antimicrobials in household products 
[1, 2]. The World Health Organization recognizes antimicrobial resistance as one 
of the three greatest threats to human health [3]. However, the antimicrobial 
pipeline remains unacceptably lean, in fact, the ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) 
have outpaced the drug discovery process [4, 5]. The number of antimicrobial 
agents approved by the United States Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA) has sharply decreased over the last 25 
years (Fig. 1). This has left few treatment options for the most stubborn forms of 
MRSA (methicillin-resistant Staphylococcus aureus). The picture is even bleaker 
for infections caused by Gram-negative bacteria, which are occasionally resistant 
to all the antibiotics now in the market. All these facts have made it necessary to 
launch different initiatives and efforts towards discovering new, safe and 
effective antimicrobials in the next decade [6]. All this work is beginning to 
crystallize, and in the last decade 20 new antibiotics have been launched and 
approximately 40 compounds are currently in active clinical development [7].  
 In this context, there is now renewed interest in the search for drugs that have 
more than one target on the bacterial cell, rather than a specific chiral receptor or 
enzyme, with a focus on modes of therapy with mechanisms less likely to 
promote resistance. Antimicrobial peptides (AMPs) are a class of antibiotics that 
has attracted great interest in the last few years because they rarely spur the 
development of resistant organisms. They are a diverse group of molecules that 
share a few common features, the most important is that their main target is the 
lipid bilayer itself, and in consequence to develop genetic resistance is very costly 
for bacteria.  
 
 
 
Figure 1. Between 1935 and 1968, 14 classes of antibiotics (with novel mechanisms of 
action) were introduced for human use; since then only 5 new classes have been described.  
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1. Antimicrobial peptides (AMPs) 
 
 Antimicrobial peptides are natural weapons produced by a variety of 
organisms, from single-celled microbes to vertebrates [8]. They are very 
diverse in their sequences, length (generally short) and structures (some of 
them are linear while others are cyclic due to disulfide bridges, with a variety 
of secondary structures) but they all adopt an amphipathic conformation with 
opposing hydrophobic and polar charged faces that allows them to interact 
and disrupt selectively negatively charged microbial membranes. They can be 
classified as follows [9]:  
 
• Anionic peptides, such as dermcidin from humans and daptomycin. 
• Linear cationic α-helical peptides, as for example magainin 2 and 
cecropins.  
• Anionic and cationic peptides enriched for specific amino acids, like 
tryptophan-rich indolicin from cattle and Dab-rich polymyxins.  
• Peptides that contain cysteine and form disulphide bonds, such as 
defensins and protegrins.  
• Peptide fragments of larger proteins, as for example lactoferricin 
from lactoferrin. 
 
 Multiple studies have shown that AMPs have very good activities (in the 
micromolar range), and broad spectrum of activity against a range of bacteria, 
fungi, enveloped viruses and parasites [10] and represent a promising novel 
class of antibiotics. Traditionally, the search of novel AMPs involved the 
identification of active peptides from natural sources followed by the design 
of synthetic peptide analogs, but nowadays design is accompanied by 
structure-function studies, or de novo design that includes high-throughput 
combinatorial library screening, structure-based modeling, predictive 
algorithms and the introduction of non-coded modifications to conventional 
peptide chemistry [11]. Some AMPs have even been discovered through 
sequence searches within large proteins (such as lactoferricin or hemoglobin). 
Some examples of AMPs introduced or in advanced stages of development 
can be found in Table 1.  
 
2. Mechanism of action of AMPs 
 
 Although the mode of action of antimicrobial peptides involves 
disrupting the integrity of the bacterial membrane in different ways,                
new evidence points to intracellular targets, including DNA and protein 
synthesis, protein folding, enzymatic activity and cell wall synthesis. In any  
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Table 1. Representative antimicrobial peptides in different stages of the drug-
discovery process (M = Marketed). 
Name Description Activity Phase Observations 
Polymyxin B 
(PxB) 
10-amino acid 
lipopeptide 
Antibacterial 
Gram- M 
First discovered in the 
1940s, but their use was 
discontinued due to 
nephrotoxicity and 
neurotoxicity 
Colistin 
(Polymyxin 
E) 
10-amino acid 
lipopeptide 
Antibacterial 
Gram- M 
Discovered in the 1950s, 
differs in 1 amino acid 
from PxB, less active than 
PxB but also less toxic 
and so preferentially used. 
Nisin 
34-amino acid 
polycyclic 
peptide 
Antibacterial 
Gram+ M 
In 2001, approved as 
antimicrobial food 
additive 
Daptomycin 13-amino acid lipopeptide 
Antibacterial 
Gram+ M 
Originally developed by 
Lilly in the early 1980s 
but abandoned after early 
clinical trials. Cubist 
Pharmaceuticals launched 
daptomycin in 2003 
Telavancin lipoglycopeptide Antibacterial Gram+ M 
Approved by the FDA in 
2009 for complicated skin 
and skin structure 
infections 
Pexiganan 
(MSI-78) 
22-amino acid 
analogue of 
magainin 2 
Broad-spectrum 
antibacterial III 
No advantage was 
demonstrated over 
existing therapies 
Iseganan  
(IB-367) 
synthetic 
protegrin 1 
Broad-spectrum 
antibacterial and 
antifungal 
III 
No advantage was 
demonstrated over 
existing therapies 
Omiganan 
(MBI-226) 
synthetic 
analogue of 
indolicidin 
Broad-spectrum 
antibacterial and 
antifungal 
III 
Failed in phase III of 
catheter-related infections 
but is actually under Phase 
III trials for acne and 
rosacea 
PAC-113 
12-amino acid 
peptide based on 
histatin 
Candidiasis 
 (C. albicans)  II 
Phase I and Phase II 
completed with promising 
results, no Phase III trials 
proposed yet 
XOMA 629 
9-amino acid 
peptide derived 
from 
bactericidal/perm
eability-
increasing 
protein (BPI) 
Impetigo II 
First tested for acne 
without demonstrating 
benefit over existing 
therapy, actually in Phase 
II trials for treatment of 
impetigo 
HB1345 synthetic lipohexapeptide 
Acne 
(Propionibacterium 
acnes) 
Pre-
clinical 
Promising due to short 
length 
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case, membrane interactions are important even for intracellular-targeting 
peptides, because they must translocate the lipid membrane. Diverse studies 
have indicated that the interaction of AMPs with the bacterial membranes is 
specifically based on their structural properties. It is thus their sequence, size, 
cationic nature, hydrophobicity and amphipathicity that govern their 
interaction with target cells [12, 13]. 
 According to the Shai-Matsuzaki-Huang (SMH) model [14-16], 
unstructured peptides adopt a three-dimensional structure when interacting 
with the bacterial membrane and fold into amphiphilic molecules, with 
positively charged sides directly interacting with the anionic lipid head-
groups of the bacterial membrane. The lipids are then displaced by the 
peptides, causing a thinning of the outer leaflet of the bacterial membrane. 
Right after this, the peptides aggregate and form a channel that allows for 
peptide translocation into the interior of the target cell (Fig. 2). At this point, 
there are three different models that have been proposed to explain the 
method of pore formation; the barrel-stove model, the torodial pore 
(wormhole) model and the micellisation model [17, 18]. There does not 
appear to be one model that fits all peptides, with various factors contributing 
to the process of pore formation. The actual antimicrobial activity in order to  
     
 
 
Figure 2. The SMH model for the mechanism of action of an AMP. The various steps 
include: carpeting of the outer leaflet, insertion of the peptide into the bilayer and 
finally collapse of the membrane or in some cases diffusion of the peptide to target the 
intracellular target. 
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kill bacteria resides in part in the disruption of the bacterial cell membrane, 
which can occur in a number of ways. These include membrane depolarization, 
permeabilization or creation of pores which could cause cellular contents to 
leak out, degradation of cell walls, and alteration of the lipid composition in 
the membrane bilayer which could lead to the disturbance of membrane 
functions [8, 19]. 
 A variety of techniques have been used to assess the mechanisms                   
of antimicrobial peptide activity. Each method provides a slightly               
different view of peptide activity and no single technique is capable of 
adequately determining the mechanism of action of AMPs. Such techniques 
include:  
 
- Biophysical studies with model membranes: To provide insights into 
mechanisms of activity and therefore determine the type of damage 
induced by the peptides, we can study the interaction of AMPs with 
phospholipids in model membranes (liposomes or monolayers), of single 
or mixed lipids in order to mimic the different composition of bacterial 
membranes. The use of fluorescent dyes can also be useful, such as 
encapsulated dyes to detect the formation of pores or labeled lipids to 
determine the effect on the bilayer [13].  
- Microscopy: The use of microscopy techniques to visualize the effects of 
AMPs on microbial cells has helped identify general target sites. 
Scanning and transmission electron microscopy have been used to 
demonstrate the ultrastructural damaging effects of antimicrobial 
peptides [20]. This analysis has shown that different peptides have 
different effects on microbial cells, indicating that they might have 
different target sites or mechanisms of activity.  
-  Circular dichroism (CD) or oriented circular dichroism (OCD): The 
orientation and secondary structure of an AMP bound to a lipid bilayer 
can be measured by CD in a controlled humidity environment with light 
incident normal to the sample surface [21].  
-  Flow cytometry (FC): Flow cytometry in conjunction with different dyes 
can be used to determine the effects of the peptides on bacteria, such as 
propidium iodide (PI) to detect membrane permeability or bis-(1,3-
dibutylbarbituric acid) trimethine oxonol [DiBAC4(3)] to detect 
depolarization of the membrane [22].  
-  Solid-state NMR spectroscopy (ssNMR): Solid-state NMR measures the 
secondary structure, orientation and penetration of AMPs into lipid 
bilayers in the biologically relevant liquid-crystalline state [23]. These 
data help define the interactions of AMPs with bacterial membranes and 
the effects of peptide and membrane composition on activity.   
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3. Mechanism of action of polymyxins 
 
 Emergence of nosocomial bacterial pathogens with acquired resistance to 
almost all available antibiotics, namely “superbugs”, is a growing medical 
concern. The major challenge is regarding the treatment of multidrug-
resistant Gram-negative bacteria, such as Pseudomonas aeruginosa or 
Acinetobacter baumannii, since no new antibiotic is even in the drug 
development pipeline with the sole exception of tigecycline. Consequently, 
there has been a resurgence of old antibiotics, such as polymyxins discovered 
in the 1940s [24], as drugs of last resort for the treatment of infections caused 
by MDR Gram-negative pathogens, despite their toxicity (nephro- and 
neurotoxicity) and the lack of clinical efficacy data [25, 26].   
 Polymyxin B (PxB) and polymyxin E (colistin) are two secondary 
metabolite nonribosomal cyclic lipopeptides produced by the soil bacterium 
Bacillus polymyxa, and are the two polymyxins used clinically. Both are 
specific and highly potent against Gram negative bacteria. They share a 
common primary sequence, with five positives charges due to L-α,γ-
diaminobutyric acid (Dab), the only difference being at position 6, which is 
occupied by D-Phe in PxB and D-Leu in colistin (Fig. 3).  
 The mechanism of action of polymyxins, and in particular of PxB, has 
been studied in detail [27]. The initial target is anionic lipopolysaccharide 
(LPS) in the outer membrane (OM) of Gram negative bacteria, resulting in 
OM permeabilizing action. The high affinity for LPS binding can be 
attributed to the polycationic character of PxB together with its 
amphipathicity, and the polar and hydrophobic domains folding in two 
distinct faces when binding to the bacterial membrane. LPS binding results in 
 
 
 
Figure 3. Structures of polymyxin B and colistin. 
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divalent cation displacement, and leads to PxB self-promoted uptake into the 
periplasmic space [28]. This process is necessary but not sufficient for bacterial 
killing, and subsequent interaction with the cytoplasmic membrane is necessary 
for antibiotic activity [28, 29]. The next step remains unclear at the molecular 
level, but biophysical studies with model membranes have given insight into the 
mechanism of bacterial killing by PxB. One possibility involves the insertion of 
PxB into the cytoplasmic membrane and the disruption of its integrity via 
membrane thinning or pore formation. However, several reports clearly show that 
permeabilization or depolarization of the membrane take place at concentrations 
of polymyxin well above the minimal inhibitory concentration (MIC), and thus 
other mechanisms of bactericidal action should be considered [12].  
 A more consistent mechanism of action is based on the formation of 
periplasmic membrane contacts between outer and inner membranes. According 
to this model, once in the periplasmic space PxB forms contacts between the two 
enclosed phospholipid interfaces and promotes a fast exchange of certain 
phospholipids. The resulting changes in the membrane lipid composition trigger 
an osmotic imbalance that leads to bacterial stasis and cell death. This 
phenomena has been proposed as the mechanism of antibacterial action of PxB 
and several other antibiotic peptides, including cecropins [30-32], and has major 
implications in bacterial resistance, since it would not be susceptible to generate 
stable genetic resistance. In fact, acquisition of resistance by a sensitive microbial 
strain against antimicrobial peptides is surprisingly improbable [8]. 
 Biophysical studies using model membranes have demonstrated that at 
the concentrations around the MIC, PxB induces the apposition of anionic 
vesicles and the formation of functional vesicle-vesicle contacts that support 
a fast and selective exchange of phospholipids exclusively between the outer 
monolayers of the vesicles in contact and maintaining intact the inner 
monolayers and the aqueous contents, as schematized in Fig. 4 [33-35]. 
  
X  
 
Figure 4. Model showing the formation of membrane contacts mediated by PxB. Key 
points are: (i) contacts involve only the outer monolayers of the apposed vesicles; (ii) 
bilayer structure is maintained; (iii) lipid transfer is selective and depends on the lipid 
headgroup composition; (iv) PxB is accessible from the aqueous phase; (v) contacts 
are stable (from [33-35]).  
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 A battery of physicochemical and biophysical methods has been applied 
to dissect and study the different events of the interaction of polymyxin              
with the lipid membrane. Overall, these methods amplificate the effect 
caused by very few molecules of peptide bound to the membrane. Unilamelar 
vesicles and monolayers at the air/water interface have been prepared with 
lipopolysaccharide (LPS from Salmonella minnesota) to reproduce the outer 
membrane of Gram-negative bacteria. To mimic the cytoplasmic membrane, 
mixtures of 1-palmitoyl-2-oleoylglycero-sn-3-phosphoglycerol (POPG) and 
1-palmitoyl-2-oleoylglycero-sn-3-phosphoethanolamine (POPE), or lipid extracts 
of Escherichia coli, have been used. 
 Lipid monolayers are valuable simplified models of biomembranes, and 
have been extensively used in the study of the interfacial properties of 
membrane active peptides.  Monolayers are bidimensional model membranes 
with a planar geometry where the lipid molecules have a defined orientation, 
and are very suitable for thermodynamic analysis [36]. Transferred to a solid 
support, lipid or lipid-peptide monolayers can be investigated by atomic force 
microscopy (AFM), a powerful technique to study the structure and 
properties of the lipid surface at a nanometric scale [37].  
 Thermodynamic analysis of mixed monolayers formed by PxB and               
E. coli lipids shows non-ideal mixing consistent with lipid-PxB domain 
formation [38]. At very low mole fractions of PxB at the interface, below 
0.04 mol fraction, monolayers had associated small positive values of excess 
Gibbs energy, thus suggesting immiscibility and formation of PxB clusters in 
the dominant lipid phase. AFM observation of transferred mixed and pure 
monolayers at the membrane equivalence pressure reveals that at the                
low concentrations of PxB required for contact formation, XPxB<0.04, the 
antibiotic interacts with the bacterial lipids in a very unique way, inducing the 
formation of well-defined microdomains that are clearly distinguishable from 
the structures formed at lytic concentrations of PxB (Fig. 5).  
 Interaction with LPS monolayers was also determined by the Langmuir 
trough technique, maintaining constant either the surface pressure or the area. 
In addition, morphological changes in the monolayer upon peptide insertion 
have been observed by Brewster angle microscopy (BAM). BAM images of 
monolayers of PxB-containing LPS or its anchoring part, lipid A, show that 
PxB induces important changes in the film morphology with the formation of 
more condensed phases at lower surface pressures [39].  
 
4. Polymyxin B synthetic analogues 
 
 In view of the excellent antimicrobial activity of the naturally occurring 
polymyxins and relatively low prevalence of resistance, it is not surprising 
that there has been substantial effort into discovery of polymyxin analogues with 
improved microbiological, pharmacological, and toxicological profiles [27].   
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Figure 5. Variation of the surface pressure with the mean molecular areas of                
mixed ECL-PxB monolayers at various peptide mol fractions: (a) 0; (b) 0.005;                  
(c) 0.01; (d) 0.17; (e) 0.36; (f) 0.56; (g) 0.77; and (h) 1. AFM images of the ECL-PxB 
L-B monolayers at 32 mN/m are shown at the right side. Bar represents 500 nm [38]. 
 
 We have designed and synthesized a series of PxB-analogues that mimic 
the primary and secondary structure of PxB [39-43]. Peptide synthesis was 
performed manually following standard Fmoc/tBu procedures, using 
DIPCDI/HOBt activation on a benzhydrylamine resin. Homogeneity of 
peptide crudes was assessed by analytical HPLC, and peptides were 
subsequently purified by preparative HPLC. Cyclization of peptides through 
disulphide bonds was carried out by air oxidation. Final purity was greater 
than 95%. Peptides were characterized by amino acid analysis with a 
Beckman 6300 analyser and by MALDI-TOF with a Bruker Model Biflex III.  
 The first analogue obtained by this method (sp-B, structure in Fig. 6), 
closely mimics the primary and secondary structure of PxB. However, to 
ensure the economic viability of the potential new drug, the simplicity of the 
synthetic process had to be considered. For this purpose, the complex bond 
between Dab4 and Thr10 of natural PxB was substituted by cyclization via an 
intramolecular disulphide bridge resulting from oxidation of two                    
cysteine residues inserted in the primary amino acid sequence, as had 
previously been reported [44], and linear nonanoic acid was introduced at the 
N-terminus. 
  Penetration of sp-B into monolayers of LPS gives information on the 
affinity of the lipopeptide for the main component of the Gram negative outer 
membrane [39]. Experiments conducted at constant pressure or at constant 
area showed that sp-B readily inserted into LPS monolayers, with even 
higher levels of affinity than the parent compound. 
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Figure 6. Sequence of PxB synthetic analogue sp-B. The two principal changes 
introduced to simplify the synthesis are highlighted. 
 
 Biophysical studies with unilamelar vesicles that model the cytoplasmic 
membrane reveal that low concentrations of sp-B form functional                
vesicle-vesicle contacts that are selective for transfer of anionic 
phospholipids [40, 41]. For example, fluorescence experiments based on the 
excimer/monomer ratio of pyrene-labeled phospholipids show that only 
monoanionic phospholipids such as 1-palmitoyl-2-oleoylglycero-sn-3-
phosphoglycerol (POPG) are transferred, whereas dianionic phospholipids 
such as 1-palmitoyl-2-oleoylglycero-sn-3-phosphate (POPA) are not.  
 This interaction is equivalent to the previously described for PxB on anionic 
membranes [35], and therefore sp-B is a valid scaffold to introduce different 
structural changes with the objective of getting more insight into the molecular 
basis of the interaction of the peptides with the lipid membrane. In this sense, 
analogues sp-C and sp-D (sequences in Table 2) were designed and synthesized. 
The contribution of the hydrophobic domain (D)Phe6-Leu7, highly conserved in 
the polymyxin family, was assessed with analogue sp-C, where a permutation in 
the sequence disrupted this hydrophobic domain. The influence of the peptide 
charges on the interaction has been explored with sp-D, an analogue that contains 
two residues of L-α,γ-diaminopropionic acid (Dap) in positions 1 and 8. Dap 
residues have a pKa approximately of 8.5 and at pH 8.0 will confer the peptide a 
much lower cationic character compared to PxB (the pKa of Dab is 9.45).  
 
Table 2. Peptide sequences. 
 
Peptide Sequence
PxB 
PxB-np 
sp-B 
sp-C 
sp-D 
R1-Dab-Thr-Dab-cyclo[Dab-Dab-(D)Phe-Leu-Dab-Dab-Thr] 
Thr-Dab-cyclo[Dab-Dab-(D)Phe-Leu-Dab-Dab-Thr] 
R2-Dab-Thr-Dab-cyclo-[Cys-Dab-(D)Phe-Leu-Dab-Dab-Cys] 
R2-Dab-Thr-Dab-cyclo-[Cys-Dab-(D)Phe-Dab-Leu-Dab-Cys] 
R2-Dap-Thr-Dab-cyclo-[Cys-Dab-(D)Phe-Leu-Dap-Dab-Cys] 
 aR1, (S)-6-methyloctanoyl ; bR2, nonanoyl; sp-B, sp-C, and sp-D are cyclized by 
means of a disulfide bond between Cys-4 and Cys-10.
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 Results in this work are summarized in Fig. 7, and show that insertion 
into the LPS layer is achieved to different extents by all the lipopeptides 
assayed, including acyl chain-lacking compound PxB-np, which corresponds 
to a deacylated PxB decapeptide (Table 2). However, insertion into the 
anionic phospholipid membrane and adoption of an active form of the 
peptides, i.e. the ability to induce phospholipid exchange, is more restrictive, 
and requires the interplay of the two hydrophobic domains of the lipopeptide 
(the acyl chain and the D-Phe-Leu region), as well as the five positive 
charges of Dab. 
 In another study, synthetic fluorescent analogs of sp-B were used to 
investigate the peptide position and orientation in the intermembrane 
contacts: sP-Bw, an analog that contains D-tryptophan (DTrp) instead of the 
naturally occurring D-phenylalanine, and sP-Bpy, incorporating a pyrene 
group at the N-terminus [41]. The inclusion of DTrp is very useful to 
characterize binding of the peptide to the membrane by fluorescence techniques. 
Tryptophan fluorescence, anisotropy and quenching measurements performed 
with sP-Bw indicate that the peptide binds and inserts in anionic vesicles of 
POPG and POPA adopting different forms. sP-Bw also serves as a donor for 
intermolecular resonance energy transfer (FRET) experiments with sP-Bpy 
used as acceptor. FRET experiments are consistent with self-association                 
of sP-B bound to anionic vesicles at the concentrations that induce the 
vesicle-vesicle contacts (Fig. 8). 
 
 
 
Figure 7. Cartoon schematic of possible interactions of the peptides with bacterial 
membranes. (Top) Lipopolysaccharide as OM model; (Bottom) Anionic phospholipid 
as IM model. Peptides represent (from left to right): PxB or sp-B; sp-D; PxB-np. 
Active forms are indicated with asterisks [39]. 
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Figure 8. (Left) Tryptophan fluorescence emission spectra of sP-Bw in 10 mM Tris 
buffer (dotted line) or bound to vesicles of (a) POPG; (b) POPA. (Right) Self-
association of sP-B bound to vesicles of POPG detected by intermolecular Trp-pyrene 
FRET. (a) sP-Bw; (b) mixture of sP-Bw and sP-Bpy; (c) same with POPG vesicles; 
peptide mol fraction 1% [41]. 
 
5. Conclusion 
 
 Naturally occurring polymyxins are cationic antimicrobial peptides 
highly effective against Gram-negative bacteria. The emergence of multiply 
antibiotic-resistant Gram-negative bacilli, frequently susceptible only to 
polymyxins, has sparked a renewed interest in these agents, and many efforts 
are directed towards the generation of new molecules with improved 
therapeutic index. For this purpose, a detailed knowledge on the mechanism 
of action of polymyxin and polymyxin derivatives in the membrane is 
fundamental.  In our group we have studied the interaction of polymyxin B 
(PxB) with lipid vesicles and monolayers prepared with a lipid composition 
that closely mimics the bacterial inner and outer membranes. Results are 
consistent with a mechanism of action based on the simultaneous interaction 
with the two membranes and alteration of the membrane composition by 
PxB-induced membrane-membrane contacts and lipid exchange. Synthetic 
PxB-analogues have been specifically designed to get more insight into the 
mechanism of action at the molecular level. Analogs with intrinsic 
fluorescence indicate that peptide self-association in the membrane is 
necessary for intermembrane contact formation, whereas analogs with 
different modifications in the hydrophobic and polar residues reveal that 
insertion and membrane activity depends on the lipid composition and is the 
result of a combination of electrostatic and hydrophobic interactions. 
Synthetic analogues that act by the same mechanism than the parent peptide 
are promising molecules in the search for new antibiotics to treat resistant 
bacteria.   
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